![]() | |
Clinical data | |
---|---|
Other names | CORT-125134 |
Routes of administration | By mouth |
Drug class | Antiglucocorticoid |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C27H22F4N6O3S |
Molar mass | 586.57 g·mol−1 |
3D model (JSmol) | |
| |
|
Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome.[1] It is also under development for the treatment of solid tumors and alcoholism.[1][2] The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor.[1] As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown.[1]
References[edit]
- ^ a b c d "Relacorilant - Corcept Therapeutics - AdisInsight".
- ^ Veneris JT, Darcy KM, Mhawech-Fauceglia P, Tian C, Lengyel E, Lastra RR, Pejovic T, Conzen SD, Fleming GF (2017). "High glucocorticoid receptor expression predicts short progression-free survival in ovarian cancer". Gynecol. Oncol. 146 (1): 153–160. doi:10.1016/j.ygyno.2017.04.012. PMC 5955699. PMID 28456378.
External links[edit]